In the Tat peptide- and Control-SH3GL2-treated groups, MDA levels were significantly elevated 3 h after ischemia and decreased 12 h post ischemia, although MDA levels were significantly higher than that of their respective controls. The gene discussed is TAT; the disease is ischemia.